IVRN Stock Overview
Innoveren Scientific Inc., a medical bioscience company that develops technology in regenerative medicine for limb salvage.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Innoveren Scientific Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.02 |
| 52 Week High | US$3.73 |
| 52 Week Low | US$0.0003 |
| Beta | 472.84 |
| 1 Month Change | -33.33% |
| 3 Month Change | -71.01% |
| 1 Year Change | n/a |
| 3 Year Change | -99.96% |
| 5 Year Change | -100.00% |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| IVRN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -28.6% | -2.5% | -3.2% |
| 1Y | n/a | -3.7% | 19.3% |
Return vs Industry: Insufficient data to determine how IVRN performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how IVRN performed against the US Market.
Price Volatility
| IVRN volatility | |
|---|---|
| IVRN Average Weekly Movement | 81.2% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: IVRN's share price has been volatile over the past 3 months.
Volatility Over Time: IVRN's weekly volatility has decreased from 32730% to 81% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 2 | Michael Yurkowsky | innoverenscientific.com |
Innoveren Scientific Inc., a medical bioscience company that develops technology in regenerative medicine for limb salvage. It is also developing immunotherapies for ovarian cancer, pancreatic cancer, and mesothelioma. The company was formerly known as H-CYTE, Inc. and changed its name to Innoveren Scientific Inc. in July 2023.
Innoveren Scientific Inc. Fundamentals Summary
| IVRN fundamental statistics | |
|---|---|
| Market cap | US$106.77k |
| Earnings (TTM) | -US$3.26m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs IVRN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IVRN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$999.00 |
| Gross Profit | -US$999.00 |
| Other Expenses | US$3.26m |
| Earnings | -US$3.26m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.61 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -40.6% |
How did IVRN perform over the long term?
See historical performance and comparison